Biotech Movers du jour: Clinical Data (CLDA) and Genoptix (GXDX)

buy modafinil nyc Novartis (NVS) acquires Genoptix(GXDX $24.84) for $470M-Stock is up 25%

The biotech diagnostics and tools sector was ignited today with acquisition of Genoptix, a provider of laboratory services for hematology and oncology. Genoptix put itself up for sale in December and is an emerging niche player in personalized medicine with revenues of about $200M and net income at the 9% level.EPS for 2011 was projected flat with sales growth at 2%+. Novartis is boosting their focus in clinical diagnostics with this acquisition as they have a major partnership with GenProbe (GPRO) for blood screening and infectious diseases.

Many diagnostics/tools stocks were up 2%or more today: Abaxis (ABAX),Cepheid (CPHD),Genomic Health (GHDX),Illumina (ILMN),Pacific Biosciences (PACB) and Quidel (QDEL). The Novartis deal gives credence to the personalized medicine strategy of targeting specific therapies with companion diagnostics.

Raygent » Biomarkers Drive Personalized Medicine

buy modafinil in south africa Clinical Data(CLDA) Gets FDA Approval For Antidepressant Drug

The FDA approved the Clinical Data product Viibryd for major depressive disorder (MDD) which  a market potential of over $600M according to one analyst. Viibryd (vilazodone HCL) is the only antidepressant that is a selective serotonin reuptake inhibitor and 5HT1A receptor partial agonist. The product was licensed from Merck KGaA. The Company was initially focused on genomics but in November 2010 sold its biomarker/pharmacogenomics business for $14.5M to Transgenomic (TBIO) in order to focus in pharmaceuticals.

Clinical Data, Inc. Announces FDA Approval of Viibryd™ (vilazodone HCl) for Major Depressive Disorder (NASDAQ:CLDA)

get link

No comments yet.

Leave a Reply